WEBINAR | Reverse Mergers and SPACs: Are APOs the New Norm for Biotechs Going Public?

Get The
Recording


ABOUT SHAREVAULT

ShareVault’s secure document sharing solution gives organizations of all sizes in all industries the confidence to simply and securely share sensitive documents with third parties during due diligence, fundraising, board communications, and any circumstance when it is crucial that confidential information is maintained under the highest level of security and control.

Compared to consumer-grade solutions, ShareVault virtual data rooms offer many features that give you control and document intelligence with the highest level of document-protection and monitoring available. Learn more.


Reverse Mergers and SPACs: Are APOs the New Norm for Biotechs Going Public?

2020 was an unprecedented year for Special Purpose Acquisition Corps (SPACs), an alternative public offering (APO) financing vehicle for listing on a public stock exchange. SPACs raised $82 billion, a figure greater than all previous years combined and representing nearly half of all capital raised in U.S. listed initial public offerings (IPOs). And the momentum continues to grow in 2021 as evidenced by 225 SPACs raising roughly $71 billion—a figure that accounts for more than 70% of all public stock sales and putting it on track to shatter last year’s record. 

Watch the on-demand webinar where Scott Jordan leads a distinguished panel of experts in a discussion on the SPAC landscape from those immersed in the sector including sponsors, a leading attorney representing SPACs, and an investment banker facilitating concurrent financings. 

In the on-demand webinar, panel members provide an overview of the financing structure, capital raised to date, case studies of closed transactions, and answers to the following questions:

  • Is my company a candidate for a SPAC?

  • Should my board evaluate SPACs as a viable alternative to an IPO?

  • How do I position my company to attract a SPAC and raise concurrent financing?

  • What are the advantages/disadvantages of going public via a SPAC, IPO, or Reverse Merger?

  • What are the key success factors for closing a SPAC and achieving post-close success?

SPEAKERS:


Company team

Scott Jordan - Moderator

Founder / CEO, S. Jordan Associates (SJA)

SJA is led by Scott Jordan, a FINRA licensed registered representative with over 30 years of experience in the life sciences industry as a C-Level / business development executive, and investment banker. During this time, Scott successfully assisted biotechnology companies to raise retail and institutionally funded private placements / public offerings, secure regional/global licensing agreements, and facilitate liquidity events via initial public offerings (IPOs), secondary offerings, and alternative public offerings (APOs).

Most recently Scott was Chief Business Officer (CBO) / Chief Financial Officer of promising early-stage companies located in Houston, Texas (Iterion Therapeutics, Salarius Pharmaceuticals) supported by non-dilutive financing provided by the Cancer Prevention Research Institute of Texas (CPRIT). Scott’s efforts at Salarius included raising Series 1 / A financing rounds advancing Salarius’ lead asset into Phase 1 / 2 clinical trials in rare, orphan disease (Ewing Sarcoma). As a result of the company achieving pivotal financing and scientific milestones, Salarius listed on NASDAQ via a reverse merger with Flex Pharma, Inc in July of 2019. Learn more...

Company team

David Strupp

Co-Chief Executive Officer, Ignyte Acquisition Corp.

David J. Strupp, Jr. is the Co-Chief Executive Officer and a member of the board of directors of Ignyte Acquisition Corp. Mr. Strupp has worked as a dedicated healthcare investment banker for 28 years at various investment banks. Mr. Strupp has served as a Managing Director and Head of Healthcare Investment Banking at Ladenburg Thalmann & Co. Inc. since May 2012. In his role leading the firm’s healthcare investment banking practice at Ladenburg Thalmann, Mr. Strupp has overseen the execution of numerous transactions across a range of products, including M&A advisory, equity and equity-linked offerings, private placements and fixed income transactions.

During his tenure at Ladenburg Thalmann, Mr. Strupp has helped the firm establish a market-leading practice advising biotechnology companies in reverse merger transactions.

Prior to joining Ladenburg Thalmann, Mr. Strupp worked as a senior member of the healthcare groups at boutique investment banks, including ThinkEquity Partners from 2002 to 2007, Canaccord Adams (now Canaccord Genuity) from 2007 to 2008, the Maxim Group from 2008 to 2009, and Rodman & Renshaw from 2009 to 2012.

He began his career on Wall Street working in the healthcare groups at UBS Securities from 1993 to 1998, NationsBanc Montgomery Securities from 1998 to 1999, and Citigroup from 1999 to 2002. Mr. Strupp received a B.A. in Economics from Bates College and an M.Sc. in Economics from the London School of Economics.

Company team

Scott Janssen

Managing Director, LS Associates

Scott Janssen is the Managing Director and Co-Founder of LS Associates, an On Demand CFO and C Level consulting firm. Scott has over 25 years of accounting, finance and operational experience working within and consulting to public and private companies within the life science and technology space.

Scott was previously a Managing Director of the Connor Group where he provided his clients with accounting and operational consulting services to support their high growth and change management needs which included numerous IPO’s and public company transition engagements.

Prior to the Connor Group, Scott served as CFO, CAO or VP of Finance for public and private venture-funded companies within the clean-tech, consumer products and software industries.  Mr. Janssen spent a decade of his career as an auditor with Ernst & Young and Grant Thornton. Scott earned his BS in Applied Mathematics from UCLA and is a licensed CPA in California (inactive). 

Company team

Stephen P. Alicanti

Partner, DLA Piper LLC (US)

Stephen Alicanti focuses his practice on the representation of issuers and underwriters in a broad range of domestic and international capital markets transactions. 

These transactions include registered offerings and private placements of equity, high-yield debt and investment-grade debt securities. Stephen regularly advises clients regarding SEC reporting and disclosure requirements and corporate governance matters. In addition, he frequently represents issuers, investment banks and investors in transactions involving special purpose acquisition companies, or SPACs. 

Stephen is also a member of the firm's Pro Bono and Hiring Committees.

Company team

Mike Montgomery

Managing Partner, Effectus Group

Mike Montgomery is the Managing Partner and founder of Effectus Group. Mike is also a lead advisory partner in the firm’s technical accounting and M&A practices, and has advised numerous life science and technology companies through the de-SPAC process. Mike has over 15 years of experience in accounting and started his career in the KPMG Silicon Valley office, working first in the audit practice and eventually in the transaction services practice. Mike is a Certified Public Accountant and holds an MBA from the U.C. Berkeley Haas School of Business.

SPONSORED BY:

Demo Logo
Demo Logo
Demo Logo
Demo Logo
Demo Logo